In this study, MS444 is used here as a tool compound for proof-of-principle for pharmacological HuR inhibition, and that targeting HuR with MS-444 has anti-tumor activity as a monotherapy in multiple pre-clinical models for CRC. The gene discussed is ELAVL1; the disease is neoplasm.